The upper cytokine-binding module and the Ig-like domain of the leukaemia inhibitory factor (LIF) receptor are sufficient for a functional LIF receptor complex

Journal of Molecular Biology

Volumn 315, Issue 4, 2002, Pages 637-646

  Aasland, Dorthe ^a   Oppmann, Birgit ^a   Grötzinger, Joachim ^a   Rose John, Stefan ^a   Kallen, Karl Josef ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Cytokine receptors; Cytokines; LIF; Ligand binding; OSM

Indexed keywords

AMINE; CYTOKINE; EPITOPE; IMMUNOGLOBULIN; INTERLEUKIN 6 RECEPTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHIMERA; CONTROLLED STUDY; DELETION MUTANT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE;

EID: 0036303448     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.2001.5282     Document Type: Article

References (75)

1. Haemopoietic receptors and helical cytokines
2. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy
3. Novel neurotrophin-1/B cell-stimulating factor-3: A cytokine of the IL- 6 family
4. Computational EST database analysis identifies a novel member of the neuropoietic cytokine family
5. IL-6 type cytokine receptor complexes: Hexamer, tetramer or both?
6. Interleukin-6 and soluble interleukin-6 receptor: Direct stimulation of gp130 and hematopoiesis
7. Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth
8. Mesenchymal to epithelial conversion in rat metanephrons is induced by LIF
9. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders
10. Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects
11. The role of IL-6 type cytokines and their receptors in bone
12. IFN beta 2/BSF2/IL-6 is the monocyte-derived HSF that regulates receptor-specific acute phase gene regulation in hepatocytes
13. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha
14. Interleukin-6 in human multiple myeloma
15. Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis
16. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury
17. The therapeutic potential of interleukin-6 hyperagonists and antagonists
18. IL-6 dependent pathology: Where do we stand and what are the options
19. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
20. Signaling through Gp130: Toward a general scenario of cytokine action
21. Evidence for the formation of a heterotrimeric complex of leukaemia inhibitory factor with its receptor subunits in solution
22. CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex
23. Signaling of the cardiotrophin-1 receptor. Evidence for a third receptor component
24. Structure-function analysis of human IL-6 receptor: Dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130
25. A role for the immunoglobulin-like domain of the human IL-6 receptor. Intracellular protein transport and shedding
26. A novel family of growth factor receptors: A common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain
27. Human growth hormone and extracellular domain of its receptor: Crystal structure and of the complex
28. Crystallogralphic evidence for preformed dimers of erythropoetin receptor before ligand activation
29. Crystal structure of a cytokine-binding region of gp130
30. Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130
31. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation
32. Identification and expression cloning of a leptin receptor, OB-R
33. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: Identification of a member of the hematopoietic growth factor receptor superfamily
34. Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): Reconstitution of a high-affinity GM-CSF receptor
35. The unusual species cross-reactivity of the leukemia inhibitory factor receptor alpha-chain is determined primarily by the immunoglobulin-like domain
36. The immunoglobulin-like module of gp130 is required for signaling by interleukin-6, but not by leukemia inhibitory factor
37. Molecular modeling-guided mutagenesis of the extracellular part of gp130 leads to the identification of contact sites in the interleukin-6 (IL-6). IL-6 receptor. Gp130 complex
38. Ligand-specific utilization of the extracellular membrane-proximal region of the gp130-related signalling receptors
39. Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes
40. Binding of leukemia inhibitory factor (LIF) to mutants of its low affinity receptor, gp190, reveals a LIF binding site outside and interactions between the two cytokine-binding domains
41. The family of the IL-6-type cytokines: Specificity and promiscuity of the receptor complexes
42. Receptor recognition sites of cytokines are organized as exchangeable modules: Transfer of the LIFR binding site from CNTF to IL-6
43. Identification of ciliary neurotrophic factor (CNTF) residues essential for leukemia inhibitory factor receptor binding and generation of CNTF receptor antagonists
44. Characterization of the receptor binding sites of human leukemia inhibitory factor and creation of antagonists
45. Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells
46. Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction
47. Combining two mutations of human interleukin-6 that affect gp130 activation results in a potent interleukin-6 receptor antagonist on human myeloma cells
48. IL-6 receptor independent stimulation of human gp130 by viral IL-6
49. Structure of an extracellular gp130 cytokine receptor signaling complex
50. LIF receptor-gp130 interaction investigated by homology modeling: Implications for LIF binding
51. The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor
52. WHAT IF: A molecular modeling and drug design program
53. 1.9 Å crystal structure of interleukin 6: Implications for a novel mode of receptor dimerization and signaling
54. Crystal structure of dimeric human ciliary neurotrophic factor determined by MAD phasing
55. Human ciliary neurotrophic factor: A structure-function analysis
56. Structural and functional studies on the human hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells
57. The crystal structure and biological function of leukemia inhibitory factor: Implications for receptor binding
58. Solution structure of leukemia inhibitory factor
59. A designer cytokine with high activity on human hematopoietic progenitor cells
60. Proliferative responses and binding properties of hematopoietic cells transfected with low-affinity receptors for leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor
61. Production and characterization of monoclonal antibodies against the leukemia inhibitory factor low affinity receptor, gp190
62. An antagonist for the leukemia inhibitory factor receptor inhibits leukemia inhibitory factor, cardiotrophin-1, ciliary neurotrophic factor, and oncostatin M
63. Inter-species chimeras of leukaemia inhibitory factor define a major human receptor-binding determinant
64. Conversion of the biological specificity of murine to human leukemia inhibitory factor by replacing 6 amino acid residues
65. Crystal structure and functional dissection of the cytostatic cytokine oncostatin M
66. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor trans-signaling responses
67. Neuropoietic cytokines in the hematopoietic fold
68. Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling
69. Influence of Interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6 receptor complex
70. Interleukin-6: Structure-function relationships
71. Analysis of the mechanism of action of anti-human interleukin-6 and anti-human interleukin-6 receptor-neutralising monoclonal antibodies
72. The membrane proximal cytokine receptor domain of the human interleukin-6 receptor is sufficient for ligand binding but not for gp130 association
73. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons
74. PCR-ligation-PCR mutagenesis: A protocol for creating gene fusions and mutations
75. Production of Leukemia Inhibitory Factor in Escherichia coli by a novel procedure and in maintaining embryonic stem cells in culture